Georgia State Spinoff Receives $225,000 To Develop Safe, Effective RSV Vaccine
Georgia State Spinoff Receives $225,000 To Develop Safe, Effective RSV Vaccine
Advac, LLC, a vaccine research company founded by Sang-Moo Kang, a professor in the Institute for Biomedical Sciences at Georgia State University, has received $225,000 from the National Institutes of Health to develop a safer, more effective vaccine for human respiratory syncytial virus (RSV).










